LJAC
KRYS icon

L.J. Altfest & Co’s Krystal Biotech KRYS Stock Holding History

L.J. Altfest & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,870
Closed -$330K – 357
2025
Q3 		$330K Buy
+1,870
New +$280K 0.04% 272

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

L.J. Altfest & Co's KRYS Position: Q4 2025 in Review

L.J. Altfest & Co sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 1,870 shares — an estimated $330K sold.

L.J. Altfest & Co first reported a position in KRYS in Q3 2025 and held it in 1 quarter. The position peaked at $330K in Q3 2025. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • L.J. Altfest & Co reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • L.J. Altfest & Co sold 1,870 Krystal Biotech shares in Q4 2025, an estimated $330K.
  • L.J. Altfest & Co first reported a position in Krystal Biotech in Q3 2025 and held it in 1 quarter.
  • L.J. Altfest & Co's Krystal Biotech position peaked at $330K in Q3 2025.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on L.J. Altfest & Co's 13F filing for Q4 2025, filed 23 Jan 2026.